Roche NimbleGen Commits to GMP and FDA Submission for Microarrays

(PresseBox) (Madison, WI, USA, ) Roche NimbleGen (SIX: RO, ROG; OTCQX: RHHBY), announced today a companywide initiative to implement Good Manufacturing Processes (GMP) for its suite of DNA microarrays. The implementation of GMP will cover the full scope of processes from development through manufacturing and will include all locations. The company plans on achieving GMP compliance followed by subsequent submission for clearance or approval of select array products to the US Food and Drug Administration.

"Roche is dedicated to providing the research, diagnostic, and pharmaceutical markets with the highest quality products possible," said Dr. Frank Pitzer, CEO of Roche NimbleGen. "We have committed our resources to achieving GMP and are continuing our discussions with the FDA to ensure compliance in our processes and products. This will enable us to provide the research and diagnostic markets with the high quality genomic tools and products they require."

As market needs change and progress, the value of the information provided from microarrays has become more interesting for markets outside of basic life science research," stated Dr. Andreas Görtz, VP of Marketing at Roche NimbleGen. "Cytogenetics is one of the first areas where there is interest to move beyond the current research studies, which will require an FDA cleared or approved product."

For more information on Roche NimbleGen, visit www.nimblegen.com

NIMBLEGEN is a trademark of Roche.
Other brands or product names are trademarks of their respective holders.

Kontakt

Roche Diagnostics Deutschland GmbH
Sandhofer Str. 116
D-68305 Mannheim
Dr. Burkhard Ziebolz
Roche Applied Science
Head Global Communication
Kary Staples
Roche NimbleGen
Social Media